Heron Therapeutics (HRTX) Cash from Investing Activities (2010 - 2026)

Heron Therapeutics has reported Cash from Investing Activities for 17 years, with the latest figure at -$939000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 141.31% year-over-year to -$939000.0; the trailing twelve-month figure through Mar 2026 stood at $12.8 million (down 35.07% YoY), and the FY2025 full-year result was $16.0 million, down 14.45% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$939000.0, up from -$5.5 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $36.8 million in Q1 2023, with the low at -$36.0 million in Q3 2022.
• Historically, Cash from Investing Activities has averaged $2.9 million across 5 years, with a median of $2.3 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 351.98% — and 2023, when it sank 537.21%.
• Heron Therapeutics' Cash from Investing Activities stood at $2.0 million in 2022, then slumped by 537.21% to -$8.8 million in 2023, then surged by 229.22% to $11.4 million in 2024, then sank by 147.78% to -$5.5 million in 2025, then surged by 82.79% to -$939000.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$939000.0 (Q1 2026), -$5.5 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.